Table 8.

Comparison of the patient responses in the clinical trials that used criteria other than RECIST v.1.1

	Mulvihill et al. (2001)						Hecht et al. (2003)	Barton et al. (2021)
Dose (viral particles)	108	109	3 × 109	1010	3 × 1010	1011	All	1011	3 × 1011	1012
Follow-up duration	Median 5.5 months						Median 6 weeks	Median 16.0 months
Timing of CT evaluations	Every 22 days						Day 35, 63 and then every 6–8 weeks	Every 2 months
Minor response/partial response (%)	33.3	33.3	66.6	16.7	0.0	0.0	9.5	0.0	0.0	0.0
Stable disease (%)	50.0	33.3	0.0	50.0	66.6	100.0	38.1	0.0	66.7	50.0
Progressive disease (%)	16.7	33.3	33.3	33.3	0.0	0.0	52.4a	66.7	33.3	50.0
Not evaluable (%)	0.0	0.0	0.0	0.0	33.3	0.0	0.0	33.3	0.0	0.0

NR not reported

^aThis figure includes patients who had to leave the study due to toxicity